JLABS
10
8M
8
1
0.20
- Areas of investment
Summary
The fund has exact preference in some founders of portfolio startups. Besides, a startup requires to be at the age of 11-15 years to receive the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Antiva Biosciences, Pionyr Immunotherapeutics, Iconic Therapeutics. Among the most successful fund investment fields, there are Health Care, Biopharma.
Deals in the range of 5 - 10 millions dollars are the general things for fund. The top activity for fund was in 2018. The fund is constantly included in less than 2 deals per year.
The usual cause for the fund is to invest in rounds with more than 10 partakers. Despite the JLABS, startups are often financed by OUP (Osage University Partners), MPM Capital, Lundbeckfonden Ventures. The meaningful sponsors for the fund in investment in the same round are OUP (Osage University Partners), Sofinnova Investments, Sirona Capital.
Investments analytics
Analytics
- Total investments
- 10
- Lead investments
- 1
- Follow on index
- 0.20
- Investments by industry
- Biotechnology (8)
- Health Care (4)
- Medical (4)
- Therapeutics (3)
- Biopharma (2) Show 8 more
- Investments by region
-
- United States (6)
- Canada (4)
- Peak activity year
- 2018
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 9
- Avg. valuation at time of investment
- 34M
- Group Appearance index
- 0.70
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Vincere Biosciences | 25 Nov 2020 | Biotechnology | Seed | 1M | United States, Massachusetts, Cambridge |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.